TY - JOUR
T1 - Statistical approaches for evaluating body composition markers in clinical cancer research
AU - Bayar, Mohamed Amine
AU - Antoun, Sami
AU - Lanoy, Emilie
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/4/3
Y1 - 2017/4/3
N2 - Introduction: The term ‘morphomics’ stands for the markers of body composition in muscle and adipose tissues. in recent years, as part of clinical cancer research, several associations between morphomics and outcome or toxicity were found in different treatment settings leading to a growing interest. we aim to review statistical approaches used to evaluate these markers and suggest practical statistical recommendations. Area covered: We identified statistical methods used recently to take into account properties of morphomics measurements. We also reviewed adjustment methods on major confounding factors such as gender and approaches to model morphomic data, especially mixed models for repeated measures. Finally, we focused on methods for determining a cut-off for a morphomic marker that could be used in clinical practice and how to assess its robustness. Expert commentary: From our review, we proposed 13 key points to strengthen analyses and reporting of clinical research assessing associations between morphomics and outcome or toxicity.
AB - Introduction: The term ‘morphomics’ stands for the markers of body composition in muscle and adipose tissues. in recent years, as part of clinical cancer research, several associations between morphomics and outcome or toxicity were found in different treatment settings leading to a growing interest. we aim to review statistical approaches used to evaluate these markers and suggest practical statistical recommendations. Area covered: We identified statistical methods used recently to take into account properties of morphomics measurements. We also reviewed adjustment methods on major confounding factors such as gender and approaches to model morphomic data, especially mixed models for repeated measures. Finally, we focused on methods for determining a cut-off for a morphomic marker that could be used in clinical practice and how to assess its robustness. Expert commentary: From our review, we proposed 13 key points to strengthen analyses and reporting of clinical research assessing associations between morphomics and outcome or toxicity.
KW - Morphomics
KW - body composition biomarkers
KW - recommendations
KW - sarcopenia
KW - statistical analysis
UR - http://www.scopus.com/inward/record.url?scp=85015926187&partnerID=8YFLogxK
U2 - 10.1080/14737140.2017.1298446
DO - 10.1080/14737140.2017.1298446
M3 - Review article
C2 - 28277100
AN - SCOPUS:85015926187
SN - 1473-7140
VL - 17
SP - 311
EP - 318
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
IS - 4
ER -